Eupraxia Pharmaceuticals Inc. (EPRX) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear

Eupraxia Pharmaceuticals ...

NASDAQ: EPRX · Real-Time Price · USD
5.38
0.02 (0.37%)
At close: Sep 05, 2025, 3:59 PM
5.39
0.19%
After-hours: Sep 05, 2025, 04:10 PM EDT

Eupraxia Pharmaceuticals Income Statement

Financials in CAD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
n/a n/a n/a n/a
Cost of Revenue
n/a 209.91K 193.27K 111.53K
Gross Profit
n/a -209.91K -193.27K -111.53K
Operating Income
-39.04K -37.2M -22.63M -20.87M
Interest Income
n/a 407.04K 569.32K 65.73K
Pretax Income
-37.01K -38.33M -23.92M -23.37M
Net Income
-36.66K -37.39M -23.26M -22.99M
Selling & General & Admin
15.71K 9.65M 5.65M 8.89M
Research & Development
23.33K 27.54M 17.2M 9.68M
Other Expenses
n/a 0.00 -0.00 n/a
Operating Expenses
39.04K 37.2M 23.2M 18.68M
Interest Expense
n/a 821.66K 1.59M 1.3M
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
39.04K 37.2M 23.2M 18.68M
Income Tax Expense
n/a 48.26K 930.52K -1.34M
Shares Outstanding (Basic)
33.37K 24.15M 19.29M 14.24M
Shares Outstanding (Diluted)
33.93K 24.15M 19.29M 14.24M
EPS (Basic)
-1.1 -1.58 -1.24 -1.61
EPS (Diluted)
-1.1 -1.58 -1.24 -1.61
EBITDA
-38.66K -36.75M -22.14M -21.96M
EBIT
-38.82K -36.9M -22.33M -22.07M
Depreciation & Amortization
163.94 149.57K 193.27K 111.53K